Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transforaminal hyaluronidase versus ozone for lumbar disc herniation pain
IRCT20181011041308N3Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of hyaluronidase, medical ozonated water, triamcinolone and ropivacaine in Herniated Lumbar Disk and lumbosacral radiculopathy (3 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Pain score at 3 months, Oswestry Disability Index at 3 months and 1 more. Started Mar 2020; status: completed.
02
Drugs
hyaluronidasemedical ozonated watertriamcinoloneropivacaine
03
Conditions
Herniated Lumbar Disklumbosacral radiculopathy
Beyond the preview
Go deeper on IRCT20181011041308N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181011041308N3.